# Nuplazid

Type: Product

Source: GetYourBrief — https://getyourbrief.com/entity/nuplazid
Canonical HTML page: https://getyourbrief.com/entity/nuplazid

## Timeline

- **2026-02-25**: Q4 Earnings Call — ACADIA reports strong year-end results and 2026 guidance.
- **2025-11-15**: Daybue Stix Launch — Launch of the granule formulation to enhance patient compliance.
- **2024-12-31**: Fiscal Milestone — ACADIA reports record quarterly revenue and achieves annual GAAP profitability.
- **2024-03-11**: Trial Setback — Phase 3 ADVANCE-2 trial for pimavanserin in schizophrenia fails to meet primary endpoint.
- **2023-04-15**: Commercial Launch — Daybue officially enters the U.S. market with strong initial uptake.
- **2023-03-10**: FDA Approval — Daybue (trofinetide) approved as the first treatment for Rett syndrome.
- **2023-03-10**: Daybue Approval — FDA approves Daybue as the first treatment for Rett syndrome.
- **2016-05-01**: Nuplazid Approval — FDA approves Nuplazid for Parkinson's disease psychosis.

## Recent coverage (3 stories, network-wide)

### Alkami Technology Signals Cloud Resilience as Banking SaaS Adoption Accelerates
2026-02-27 12:49:14 · Sector: saas · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Alkami Technology reported strong Q4 2025 results, highlighting a significant shift toward cloud-native digital banking platforms among regional financial institutions. The company's performance, alongside ACADIA Pharmaceuticals' commercial growth, underscores a resilient market for specialized SaaS and high-margin healthcare solutions.
Full story: https://getsaasbrief.com/story/alkami-technology-q4-2025-earnings-analysis

### ACADIA Pharmaceuticals Solidifies Rare Disease Leadership in Q4 Results
2026-02-27 12:48:03 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

ACADIA Pharmaceuticals delivered a strong Q4 performance, underscored by the rapid adoption of Daybue and the resilience of its Parkinson’s franchise. The results highlight a successful transition into a diversified commercial-stage biotech with a clear path to sustained profitability.
Full story: https://getbiobrief.com/story/acadia-pharmaceuticals-q4-2025-earnings-analysis

### ACADIA Pharmaceuticals Q4 Earnings: Rare Disease Pivot Drives Record Growth
2026-02-27 12:47:29 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

ACADIA Pharmaceuticals reported a transformative fourth quarter, highlighted by the rapid commercial expansion of Daybue for Rett syndrome and the steady performance of Nuplazid. The company has successfully achieved GAAP profitability, signaling a robust shift toward a diversified rare disease and neurology portfolio.
Full story: https://gethealthbrief.com/story/acadia-pharmaceuticals-q4-earnings-rare-disease-growth

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.